These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26287674)

  • 1. Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.
    Gómez-Grau M; Garrido E; Cozar M; Rodriguez-Sureda V; Domínguez C; Arenas C; Gatti RA; Cormand B; Grinberg D; Vilageliu L
    PLoS One; 2015; 10(8):e0135873. PubMed ID: 26287674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations.
    Sabbavarapu NM; Shavit M; Degani Y; Smolkin B; Belakhov V; Baasov T
    ACS Med Chem Lett; 2016 Apr; 7(4):418-23. PubMed ID: 27096052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational readthrough-promoting drugs enhance pseudoknot-mediated suppression of the stop codon at the Moloney murine leukemia virus gag–pol junction.
    Green L; Goff SP
    J Gen Virol; 2015 Nov; 96(11):3411-3421. PubMed ID: 26382736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression.
    Roy B; Friesen WJ; Tomizawa Y; Leszyk JD; Zhuo J; Johnson B; Dakka J; Trotta CR; Xue X; Mutyam V; Keeling KM; Mobley JA; Rowe SM; Bedwell DM; Welch EM; Jacobson A
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12508-12513. PubMed ID: 27702906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses.
    Fenzl CR; Teramoto K; Moshirfar M
    Clin Ophthalmol; 2015; 9():1633-44. PubMed ID: 26379420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.
    Canals I; Benetó N; Cozar M; Vilageliu L; Grinberg D
    Sci Rep; 2015 Sep; 5():13654. PubMed ID: 26347037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot-Marie-Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in
    Benslimane N; Miressi F; Loret C; Richard L; Nizou A; Pyromali I; Faye PA; Favreau F; Lejeune F; Lia AS
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
    Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.
    Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy of Sphingolipid Metabolic Disorders.
    Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases.
    Bidou L; Bugaud O; Merer G; Coupet M; Hatin I; Chirkin E; Karri S; Demais S; François P; Cintrat JC; Namy O
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2122004119. PubMed ID: 35994666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucosamine amends CNS pathology in mucopolysaccharidosis IIIC mouse expressing misfolded HGSNAT.
    Pan X; Taherzadeh M; Bose P; Heon-Roberts R; Nguyen ALA; Xu T; Pará C; Yamanaka Y; Priestman DA; Platt FM; Khan S; Fnu N; Tomatsu S; Morales CR; Pshezhetsky AV
    J Exp Med; 2022 Aug; 219(8):. PubMed ID: 35704026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.
    D'Avanzo F; Zanetti A; De Filippis C; Tomanin R
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for mucopolysaccharidosis type III.
    Seker Yilmaz B; Davison J; Jones SA; Baruteau J
    J Inherit Metab Dis; 2021 Jan; 44(1):129-147. PubMed ID: 32944950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of p.R50X
    Tarrasó G; Real-Martinez A; Parés M; Romero-Cortadellas L; Puigros L; Moya L; de Luna N; Brull A; Martín MA; Arenas J; Lucia A; Andreu AL; Barquinero J; Vissing J; Krag TO; Pinós T
    Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31848135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum starvation enhances nonsense mutation readthrough.
    Wittenstein A; Caspi M; David Y; Shorer Y; Nadar-Ponniah PT; Rosin-Arbesfeld R
    J Mol Med (Berl); 2019 Dec; 97(12):1695-1710. PubMed ID: 31786671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational readthrough of
    Lombardi S; Ferrarese M; Marchi S; Pinton P; Pinotti M; Bernardi F; Branchini A
    RNA Biol; 2020 Feb; 17(2):254-263. PubMed ID: 31613176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Aminothiazole-4-carboxamides Enhance Readthrough of Premature Termination Codons by Aminoglycosides.
    Rabea SM; Baradaran-Heravi A; Balgi AD; Krause A; Hosseini Farahabadi S; Roberge M; Grierson DS
    ACS Med Chem Lett; 2019 May; 10(5):726-731. PubMed ID: 31097990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal diseases: Overview on current diagnosis and treatment.
    Poswar FO; Vairo F; Burin M; Michelin-Tirelli K; Brusius-Facchin AC; Kubaski F; Souza CFM; Baldo G; Giugliani R
    Genet Mol Biol; 2019; 42(1 suppl 1):165-177. PubMed ID: 31067291
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.